Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Bushnell

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Endocrinology and Metabolism Clinics of North America|February 26, 2011
Standard imaging techniques for neuroendocrine tumorsDavid L Bushnell, Richard P Baum
Surgical Oncology Clinics of North America|March 11, 2020
Overview and Current Status of Peptide Receptor Radionuclide TherapyDavid L Bushnell, Kellie L Bodeker
Nuclear Medicine Communications|May 14, 2005
Comparison of cardiac to hepatic uptake of 99mTc-tetrofosmin with and without adenosine infusion to predict the presence of haemodynamically significant coronary artery diseaseShayne R Squires, David L Bushnell, Yusuf Menda, et al.
Technology in Cancer Research & Treatment|January 27, 2009
Modeling combined radiopharmaceutical therapy: a linear optimization frameworkIan M Besse, Mark T Madsen, David L Bushnell, et al.
Cancer|December 15, 2006
Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone painOliver Sartor, Robert H Reid, David L Bushnell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 5, 2026
A Phase 0 Imaging Trial of [<sup>203</sup>Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [<sup>212</sup>Pb]Pb-VMT-α-NETStephen A Graves, David L Bushnell, Michael K Schultz, et al.
EJNMMI Research|June 28, 2015
Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumorsDavid L Bushnell, Mark T Madsen, Thomas O'cdorisio, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2006
Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic modelMark T Madsen, David L Bushnell, Malik E Juweid, et al.
Nuclear Medicine Communications|July 22, 2004
99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphomaDavid L Bushnell, Yusuf Menda, Mark T Madsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 31, 2021
Addition of <sup>131</sup>I-MIBG to PRRT (<sup>90</sup>Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine TumorsDavid L Bushnell, Kellie L Bodeker, Thomas M O'Dorisio, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Endocrinology and Metabolism Clinics of North America|February 26, 2011
Standard imaging techniques for neuroendocrine tumorsDavid L Bushnell, Richard P Baum
Surgical Oncology Clinics of North America|March 11, 2020
Overview and Current Status of Peptide Receptor Radionuclide TherapyDavid L Bushnell, Kellie L Bodeker
Nuclear Medicine Communications|May 14, 2005
Comparison of cardiac to hepatic uptake of 99mTc-tetrofosmin with and without adenosine infusion to predict the presence of haemodynamically significant coronary artery diseaseShayne R Squires, David L Bushnell, Yusuf Menda, et al.
Technology in Cancer Research & Treatment|January 27, 2009
Modeling combined radiopharmaceutical therapy: a linear optimization frameworkIan M Besse, Mark T Madsen, David L Bushnell, et al.
Cancer|December 15, 2006
Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone painOliver Sartor, Robert H Reid, David L Bushnell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 5, 2026
A Phase 0 Imaging Trial of [<sup>203</sup>Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [<sup>212</sup>Pb]Pb-VMT-α-NETStephen A Graves, David L Bushnell, Michael K Schultz, et al.
EJNMMI Research|June 28, 2015
Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumorsDavid L Bushnell, Mark T Madsen, Thomas O'cdorisio, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2006
Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic modelMark T Madsen, David L Bushnell, Malik E Juweid, et al.
Nuclear Medicine Communications|July 22, 2004
99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphomaDavid L Bushnell, Yusuf Menda, Mark T Madsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 31, 2021
Addition of <sup>131</sup>I-MIBG to PRRT (<sup>90</sup>Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine TumorsDavid L Bushnell, Kellie L Bodeker, Thomas M O'Dorisio, et al.
Pageof 3